Pfizer hands another asset to Roivant
Does yesterday’s deal with Roivant mean the pharma giant is cooling on TL1A targeting? And what about Prometheus?
Lantheus has three shots on goal to challenge Novartis
Two days after tying up with Point the company outlines plans to dominate PSMA-based prostate cancer screening and treatment.
Lantheus gets to the Point in therapeutics
Lantheus goes further into radioligand therapeutics, but the market thinks its latest push shortchanges Point Biopharma.
Ionis gets into gene editing
The company insists its $80m tie-up with Metagenomi will not lead to a loss of focus.
AHA 2022 – Idorsia and Cincor move forward in hypertension
Aprocitentan’s effect size falls short of expectations, raising the risk that J&J might cool on its Idorsia partnership, while Cincor remains one to watch.
